Welcome to our dedicated page for Illumina SEC filings (Ticker: ILMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Illumina Inc (ILMN) SEC filings, offering a view into the company’s regulatory disclosures, financial reporting, and material corporate events. Illumina’s common stock is registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Stock Market LLC under the symbol ILMN, as noted in multiple Form 8-K filings.
Investors and analysts can use this filings feed to review Illumina’s current and historical reports, including Forms 10-K and 10-Q referenced in company press releases, as well as Form 8-K filings that detail significant events. Recent 8-Ks describe preliminary unaudited financial results, quarterly earnings announcements, and capital markets transactions such as the issuance of 4.750% notes due 2030 under an existing indenture, along with expected uses of proceeds for general corporate purposes and potential acquisitions.
Filings also outline material agreements and strategic transactions. For example, an 8-K dated June 22, 2025 describes a Stock Purchase Agreement under which Illumina will acquire Standard BioTools’ aptamer-based and functional proteomics business, including SomaLogic, subject to regulatory approvals and customary closing conditions. These documents provide details on purchase price, milestone payments, regulatory conditions, and termination provisions.
On Stock Titan, SEC filings for Illumina are paired with AI-powered summaries designed to highlight key elements of each document. Users can quickly identify important information in annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K), as well as access data on registered securities and capital structure. Real-time updates from EDGAR ensure that new filings, including any future debt offerings, material agreements, or other reportable events, appear promptly, while AI-generated overviews help readers navigate complex regulatory language more efficiently.
ILLUMINA, INC. Chief Legal Officer Scott M. Davies reported an open-market sale of common stock. On February 20, 2026, he sold 1,336 shares of Illumina common stock at an average price of $116.18 per share. After this transaction, he directly owned 16,334 shares of common stock.
Illumina affiliate Scott Davies reported an insider sale: 323 common shares were sold on
ILLUMINA, INC. senior vice president and chief technology officer Steven Barnard reported a Form 4 transaction involving company common stock. On February 15, 2026, he disposed of 1,259 shares in a tax-withholding disposition to cover tax obligations, a non-open-market event. After this transaction, he directly owned 33,435 shares of Illumina common stock.
ILLUMINA, INC. executive Scott D. Ericksen, the VP and Chief Accounting Officer, reported a Form 4 transaction involving a tax-related share disposition. On February 15, 2026, he disposed of 694 shares of Common Stock in a tax-withholding transaction at $116.51 per share, leaving him with 13,229 directly owned shares.
ILLUMINA, INC. Chief of Global Operations Kevin Carl Pegels reported a Form 4 transaction involving company common stock. On this date, he disposed of 1,164 shares at a price of $116.51 per share to satisfy tax obligations by delivering shares rather than paying cash. After this tax-withholding disposition, he directly holds 22,721 shares of Illumina common stock.
Illumina, Inc. Chief Legal Officer Scott M. Davies reported a tax-related share disposition. On
ILLUMINA, INC. Chief Executive Officer Jacob Thaysen reported a Form 4 transaction involving a tax-related share disposition. On this transaction, 6,544 shares of common stock were withheld at a price of $116.51 per share to cover tax liabilities, and he held 83,339 shares directly afterward.
ILLUMINA, INC. senior vice president Jakob Wedel Christensen reported a tax-withholding disposition of 578 shares of common stock at
Following this Form 4 transaction, he directly owned 10,374 shares of Illumina common stock, reflecting his remaining equity stake after the tax-related share delivery.
Illumina, Inc. SVP and Chief People Officer Patricia Leckman reported two stock transactions. She sold 2,370 shares of common stock in an open-market sale at
Morgan Stanley Smith Barney LLC filed a Form 144 notice listing the proposed sale of Common stock related to ILMN. The filing lists 2,370 shares with an aggregate value of $275,346.60 and a date of 02/18/2026. The excerpt also shows two restricted stock items dated 11/05/2024 (637 shares) and 01/05/2025 (1,733 shares).